383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Pablo Fernandez-Penas; Matteo Carlino; Katy Tsai; Victoria Atkinson; Monaster Shaheen; Sajeve Thomas; Catalin Mihalcioiu; Tom Van Hagen; Rachel Roberts-Thomson; Andrew Haydon; Andrew Mant; Marcus Butler; Gregory Daniels; Elizabeth Bunchbinder; John Hyngstrom; Mecker Moller; Igor Puzanov; C Lance Cowey; Eric Whitman; Carmen Ballesteros-Merino; Shawn Jensen; Bernard Fox; Emmett Schmidt; Scott Diede; Rebecca Setta; Jendy Sell; David Canton; Sandra Aung; Christopher Twitty; Sunny Xie; Ying Lu; Bridget O’Keefe; Alain Algazi; Adil Daud

doi:10.1136/jitc-2021-SITC2021.383

Citation Tools

Regular and Young Investigator Award Abstracts

Clinical Trials Completed

383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Fernandez-Penas P, Carlino M, Tsai K, et al

383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.383

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password